• Tiếng Việt
  • English
Catalog number: 10047

The Unyvero HPN Cartridge integrates all relevant analysis steps for the pneumonia test:

  • DNA isolation
  • Multiplex endpoint PCR
  • Amplicon detection through hybridization on membrane arrays


The Unyvero HPN Cartridge is equipped with integrated reagent containers, a DNA purification column, eight separate PCR chambers, and a corresponding number of arrays. The cartridge contains buffers for DNA purification, reagents and fluorescence-marked primers for PCR amplification, and probes for array hybridization. 

The cartridge is assembled by inserting the Unyvero Sample Tube containing the lysed sample, and by inserting the Unyvero Master Mix Tube. Once assembled, the cartridge is physically closed, minimizing the risk of contamination.

An internal control (a synthetic gene without any significant homology to known sequences) is included in the cartridge to verify DNA purification, PCR and array hybridization for each measurement. This gene is amplified in each of the eight PCR chambers and hybridized on each array.


Gram-positive bacteria

Enterobacteriales Non-fermenting bacteria Others / Fungi Resistence -  Gene

Staphylococcus aureus

Streptococcus pneumoniae

Citrobacter freundii

Escherichia coli

Enterobacter cloacae complex

Klebsiella aerogenes (E.aerogenes)

Proteus spp.

Klebsiella pneumoniae

Klebsiella oxytoca

Klebsiella variicola

Serratia marcescens

Morganella morganii

Moraxella catarrhalis

Pseudomonas aeruginosa

Acinetobacter baumannii complex

Stenotrophomonas maltophilia

Legionella pneumophila

Pneumocystis jirovecii

Haemophilus influenzae

Mycoplasma pneumoniae

Chlamydia (Chlamydophila) pneumoniae

Macrolide/Lincosamide - ermB

Oxacillin - mecA/mecC

Penicillin - tem/shv

3rd generation Cephalosporins - ctx-M

Carbapenem - kpc, imp, ndm, oxa-23, oxa-24/40, oxa-48, oxa-58, vim

Sulfonamide - sul1

Fluoroquinolone - gyrA83, gyrA87



Pneumonia is an acute infection of the respiratory system with a high incidence rate, and in hospitalized patients is usually caused by bacteria. 5% of hospitalized patients develop this rapidly progressive condition with mortality rates of up to 30%1 , and an average hospital stay of 11 to 14 days.

Current standard diagnosis uses microbiological cultures to detect bacteria and antibiotic resistances of these bacteria. However, these results are not available until one to five days later. Due to the lack of diagnostic results, most pneumonia cases are treated empirically. This is accompanied by a high rate (~40%) of initially inadequate antibiotic treatments. Studies demonstrated that an early, targeted antibiotic treatment can significantly reduce both the mortality rate and the length of hospital stay.

The Unyvero HPN Application was developed to improve diagnosis of pathogens and resistances in acute bacterial pneumonia. It

  • allows the testing of samples from sputum, respiratory aspirates (tracheal and bronchial secretions), and bronchial lavages
  • combines all analytical steps in one complete test format
  • reduces the test procedure to a few simple manual steps
  • detects simultaneously various microorganisms and antibiotic resistance markers in approx. 5 hours

Order information

Unyvero HPN Hospitalized Pneumonia Cartridge

Code 10047

Customer reviews